http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
정영범,김영곤,황태곤,김동선,이정주,김현희,전성수,박영요,임정식,문영태,박광성,이춘용 大韓泌尿器科學會 2002 Korean Journal of Urology Vol.43 No.6
PURPOSE: To investigate the biochemical change in serum and 24-hour urine after therapy with Urocitra® in patients affected by urolithiasis, who had hypocitraturia alone or associated with other metabolic disorder.<br> MATERIALS AND METHODS: One hundred eighteen patients with evidence of 1 or more stone attacks within the last 3 years participated in the present study. They were 78 men and 40 women (6 to 78 years old, with a mean age of 47.01±12.95 years). All of the patients received 15 to 20㎖ of Urocitra®-solution or 5 g of Urocitra®-C powder, three or four times daily for 3 months. Before treatment, 24-hour urine and venous blood samples were obtained, while patients were maintained on a random diet, and analyzed for various stone risk factors. After 1 week, 1 month and 3 months of treatment, samples were again obtained and analyzed in the same manner. Thereafter, we compared the biochemical values before and after treatment.<br> RESULTS: In all three follow-up periods Urocitra® induced a significant increase in urinary citrate (p<0.001) level. Urinary potassium (p<0.001), pH (p<0.001) and total volume (p<0.05) also increased significantly after 1 and 3 months of therapy, as did urinary citrate excretion in patients with hypocitraturia and normocitraturia. Urocitra® did not alter calcium, sodium or phosphorus urinary excretion. There was no significant change of serum chemistry after administration.<br> CONCLUSIONS: Urocitra® was effective in increasing urinary pH and citrate. Furthermore, it was relatively free of side effects, except for minor gastrointestinal distress. Thus, our study provides physiological and clinical validation for the use of Urocitra® in patients affected by urolithiasis, who have hypocitraturia alone or associated with another metabolic disorder.
Joo Yong Lee,Seok Young Lee,Young Woo Son,Young-Ha Oh,Jae-Hang Shim,Hong Yong Choi,Tchun Yong Lee,Hong Sang Moon 대한비뇨기종양학회 2010 대한비뇨기종양학회지 Vol.8 No.1
Pheochromocytomas of the bladder are rare tumors that arise from chromaffin tissues of neuroectodermal origin (primarily the adrenal medulla). Pheochromocytomas are extra-adrenal in approximately 10% of all cases and are termed paragangliomas. Hematuria and hypertension during urination are the most common symptoms and signs of bladder pheochromocytomas, along with generalized symptoms due to elevated catecholamines, such as headaches, blurred vision, palpitations, and flushing. Herein we report a case of a pheochromocytoma of the bladder presenting with cardiovascular symptoms and normal catecholamine levels.
Tumor Necrosis Factor와 Interleukin - 2가 신세포암환자의 종양침윤림프구 세포독성 활성화에 미치는 영향
이춘용,최홍용,우영남 한양대학교 의과대학 1994 한양의대 학술지 Vol.14 No.1
In an attempt to increase the potency of tumor infiltrating lymphocytes(TIL) in immunotherapy, the effect of tumor necrosis factor(TNF) and interleukin-2(IL-2) were investigated in vitro on proliferation and cytotoxic effect of TIL to the vatious kinds of tumor lines and fresh frozen tumor cells from renal cell carcinoma patient. The dosage of TNF was 500 unit/ml and IL-2 was 1000 Cetus unit/ml. The cytotoxicity of TIL was checked with 4 hour Chromium release cytotoxicity of TIL was checked with 4 hour Chromium release cytotoxicity assay and its proliferatio was checked by {³H} thymidine uptake assay. For the target cell of the TIL cytotoxicity was used M-14(melanoma cell line) as a lymphokine activated killer(LAK) cell sensitive cell line for investigation of LAK activity and K562(erythroleukemic cell line) for investigation of natural killer(NK) cell activity. To investigate the specific cytotoxicity on renal cell carcinoma, autologous tumor cell line was used as the autologous target. To investigate the non specific cytotoxicity on renal cell carcinoma, allogeneic fresh frozen renal carcinoma cells and renal cell carcinoma cell line(444) were used as the allogeneic target cells. The proliferation effect of TIL, treated with IL-2 at 20th day of culture was 11486±591 cpm and 23871±1069 cpm with combination of TNF and IL-2. The nonspectific cytotoxicity of TIL for the 444 at 20th day of culture was 8.2 LU in IL-2 only and 19.0 LU with combination of TNF and IL-2. The cytotoicity of TIL for the K562 at 20th day of culture was 37.3 LU in IL-2 only and 60.4 LU with combination of TNF and IL-2. These result suggest that the combination of TNF and IL-2 has a synergistic effect on proliferation and nonspectific cytotoxicity of TIL at 20th day of culture in vitro. THese results bear important practical implication for clinical trials of TIL in adoptive immunotherapy for metastatic renal cell carcinoma.